Bipolar Depression Requires a Different Treatment Framework
The depressive phase of bipolar disorder can affect energy, motivation, concentration, sleep, relationships, work, and the ability to complete basic daily tasks. For many people, depression occupies more of the illness than mania or hypomania and creates the greatest disruption to quality of life.
Because the symptoms can resemble major depressive disorder, it may seem logical to treat bipolar depression with the same antidepressants commonly used for unipolar depression. The concern is not that antidepressants can never have a role. It is that an antidepressant alone is generally not considered a complete treatment for bipolar disorder, particularly bipolar I disorder.
Antidepressants may provide limited benefit for some people, and they can sometimes contribute to mania, hypomania, mixed symptoms, or unstable mood cycling. The risks and potential benefits vary according to the type of bipolar disorder, the medication, the person’s history, and whether mood-stabilizing treatment is already in place.
At Wholistic Health, we meet people from Mobile and across the Gulf Coast who have spent years trying to treat depression without understanding why standard approaches have not provided lasting stability. When someone asks us about bipolar depression treatment in the Mobile area, we begin by looking at the full course of the illness rather than focusing only on the current low mood.
Bipolar Depression Is Not the Same as Unipolar Depression
Major depressive disorder and bipolar depression can share many symptoms, including:
- Persistent sadness or emotional numbness
- Loss of interest or pleasure
- Fatigue and slowed activity
- Sleep or appetite changes
- Difficulty concentrating
- Feelings of hopelessness or worthlessness
- Thoughts of death or suicide
The difference becomes clearer when we look beyond the depressive episode.
Bipolar disorder also involves a history of mania or hypomania. These episodes may include unusually elevated or irritable mood, increased energy, reduced need for sleep, rapid speech, racing thoughts, impulsive decisions, inflated confidence, or activity that is noticeably different from the person’s usual behavior.
A person experiencing hypomania may not recognize it as a problem. They may remember feeling productive, social, creative, or unusually confident rather than “sick.” Family members may be more likely to notice the change. This is one reason bipolar II disorder can be missed when someone seeks care only during depressive episodes.
We consider this distinction essential. Treating the current symptoms without understanding the longer mood history can lead to a plan that does not address the underlying disorder. Our article on mood disorder signs and symptoms outlines key features that help distinguish between different mood conditions.
Why an Antidepressant Alone Can Miss the Bigger Picture
Antidepressants are designed to reduce depressive symptoms, but bipolar care must also account for mood elevation, mixed symptoms, cycling, sleep patterns, and the prevention of future episodes.
For some people with bipolar disorder, an antidepressant taken without a mood-stabilizing medication may contribute to:
- A manic or hypomanic episode
- Agitation or irritability
- Depressive and manic symptoms occurring together
- More frequent mood episodes
- A reduced need for sleep accompanied by increased energy
- Impulsive or risky behavior
These outcomes do not occur in every patient, and the evidence surrounding antidepressant use in bipolar depression is nuanced. Bipolar I and bipolar II disorder are not identical, and certain people may receive an antidepressant as part of a carefully supervised combination treatment.
The central point is that antidepressant monotherapy should not be treated as the automatic answer to every depressive episode. Mood stability and the person’s history must remain part of the decision.
Someone who appears to have treatment-resistant depression may need a fresh look at the diagnosis, especially when several antidepressants have not helped or have caused unusual activation.
The Diagnosis Comes Before the Next Prescription
Bipolar disorder can take years to recognize because the depressive periods often bring people into care, while previous hypomanic symptoms may not be reported or remembered as concerning.
Before assuming that another antidepressant is the next step, a qualified mental health professional may ask about:
- Periods of unusually high or irritable mood
- Reduced need for sleep without feeling tired
- Rapid speech or racing thoughts
- Sudden increases in activity or goal-directed behavior
- Impulsive spending, sexual behavior, travel, or business decisions
- Previous reactions to antidepressants
- Psychotic symptoms
- Substance use
- Family history of bipolar disorder
- Seasonal or recurring patterns in mood episodes
Other conditions can also complicate the picture. Attention-deficit/hyperactivity disorder, anxiety, trauma-related symptoms, substance use, sleep disorders, thyroid disease, and medication effects may overlap with or worsen bipolar symptoms.
Our article on the differences between ADHD and bipolar disorder explains why a careful history matters when distractibility, impulsivity, restlessness, or high energy are present.
No online checklist can confirm a bipolar diagnosis. Diagnosis depends on the severity, duration, timing, and lifetime pattern of symptoms, along with medical and family history.
What a Broader Bipolar Depression Plan May Include
Bipolar depression treatment usually begins with medications selected for their ability to address the depressive episode without ignoring mood stabilization.
Depending on the type of bipolar disorder, previous treatment, current symptoms, and overall health, a psychiatric prescriber may consider mood stabilizers or certain atypical antipsychotic medications. Evidence-based guidelines include options such as lithium, lamotrigine, quetiapine, lurasidone-based regimens, cariprazine, and lumateperone, among others.
The right medication is not determined by a single list. Each option has different indications, side effects, interactions, monitoring needs, and potential roles in acute or long-term care.
A comprehensive plan may also include:
- Psychotherapy adapted for bipolar disorder
- Education about early warning signs
- A consistent sleep and activity schedule
- Mood tracking
- Attention to alcohol or substance use
- Support for family members
- Management of medical conditions
- A plan for preventing future episodes
At Wholistic Health, we value a whole-person view of care, but lifestyle support does not replace appropriate psychiatric treatment. Sleep, nutrition, stress management, and supportive routines may strengthen a treatment plan, while mood-stabilizing care remains central. For a broader look at how different therapy approaches are used, see our post on different types of therapy for bipolar disorder.
Where IV Ketamine May Fit
Some people continue to experience severe bipolar depression despite reasonable trials of mood-stabilizing medications and other established treatments. For selected patients, IV ketamine may be considered as an adjunctive option.
Ketamine works through the glutamate system and NMDA receptors, giving it a different mechanism from conventional antidepressants. Small randomized trials and subsequent reviews have reported rapid reductions in depressive symptoms among some participants with treatment-resistant bipolar depression.
That evidence is encouraging, but it remains more limited than the evidence for ketamine in unipolar treatment-resistant depression. Many studies have included small groups, short follow-up periods, or a single infusion. Researchers are still examining repeated treatment, durability, long-term safety, and the risk of mood switching.
IV ketamine for bipolar depression is an off-label use. It is not FDA-approved for bipolar depression, and we do not present it as a cure, a guaranteed response, or a replacement for mood-stabilizing care.
Our overview of IV ketamine for depression provides additional information about the treatment process and the distinction between off-label IV ketamine and treatments with formal depression indications.
We Evaluate More Than the Current Depressive Symptoms
When someone with bipolar depression asks us about IV ketamine treatment, we need to understand more than how severe the depression feels that day.
The evaluation may include:
- The bipolar diagnosis and subtype
- Previous manic, hypomanic, or mixed episodes
- Current mood-stabilizing treatment
- Past medication trials and reactions
- History of psychosis
- Current sleep and activity patterns
- Medical conditions and vital signs
- Substance-use history
- Current safety concerns
- Coordination with the existing psychiatric prescriber
IV ketamine is not a stand-alone treatment for the full course of bipolar disorder. When it is considered, we view it as one possible part of a broader plan and coordinate with the clinician managing the patient’s ongoing psychiatric medications when appropriate.
Active mania, mixed symptoms, psychosis, or significant instability may require a different treatment pathway or level of care. An infusion consultation should never replace urgent psychiatric assessment when safety is at risk.
Not Every Depression Treatment Automatically Fits Bipolar Depression
Because we offer more than one depression service at Wholistic Health, patients sometimes ask whether SPRAVATO® or TMS can also be used for bipolar depression.
A bipolar diagnosis changes that conversation.
SPRAVATO® is an esketamine nasal spray with FDA-approved indications for specific presentations of major depressive disorder. Those indications do not include bipolar depression. A person with bipolar disorder should not be treated as an ordinary treatment-resistant major depression case simply because antidepressants have not worked.
Our NeuroStar TMS program is also positioned primarily for major depressive disorder. TMS has been studied in bipolar depression, but research interest is not the same as a verified clinic service pairing or an FDA-cleared bipolar depression indication.
We do not assume either treatment is appropriate based only on the presence of depressive symptoms. The exact diagnosis, regulatory indication, treatment history, and clinical risks must guide the recommendation.
Common Questions About Bipolar Depression Treatment
Why can antidepressants make bipolar disorder worse?
Antidepressants may contribute to mania, hypomania, mixed symptoms, or more unstable cycling in some people with bipolar disorder, particularly when used without mood-stabilizing treatment.
The risk is not identical for every person or medication. A psychiatric prescriber must weigh the potential benefit against the person’s bipolar subtype, prior reactions, current medications, and history of mood switching.
Does an antidepressant reaction prove that I have bipolar disorder?
No. Feeling restless, anxious, emotionally numb, or physically unwell on an antidepressant does not automatically establish a bipolar diagnosis.
However, a clear period of reduced sleep, unusually elevated or irritable mood, increased energy, rapid speech, impulsive behavior, or other manic symptoms after starting an antidepressant deserves prompt clinical attention.
How can I tell whether my depression may be bipolar?
Possible clues include a history of mania or hypomania, repeated mood episodes, family history of bipolar disorder, unusual activation on antidepressants, or depressive episodes accompanied by mixed symptoms.
These signs are not enough for self-diagnosis. A qualified mental health professional needs to review symptoms across the person’s lifetime and rule out medical, medication-related, and substance-related causes.
Is IV ketamine safe for someone with bipolar disorder?
Research suggests IV ketamine may be tolerated by carefully selected patients receiving concurrent mood-stabilizing care, but the evidence remains limited. Potential risks include dissociation, blood-pressure changes, nausea, sedation, misuse concerns, and possible mood switching.
We review the complete psychiatric and medical history before making a recommendation. No treatment is risk-free, and no outcome can be guaranteed.
Would I stop my mood stabilizer before ketamine treatment?
Patients should not stop a mood stabilizer or other psychiatric medication without instructions from the prescribing clinician.
Ketamine research in bipolar depression has generally evaluated it as an adjunct to ongoing mood-stabilizing treatment rather than as a replacement. Any medication change should be coordinated with the person’s psychiatric prescriber.
What happens during an evaluation at Wholistic Health?
We review the diagnosis, treatment history, current medications, previous manic or hypomanic symptoms, medical history, and potential safety concerns. We also consider whether the patient has appropriate ongoing psychiatric care for the broader course of bipolar disorder.
The purpose of the evaluation is not to move every patient toward an infusion. It is to determine whether the service fits the clinical picture and to explain the evidence, limitations, risks, and alternatives clearly.
What to Remember About Antidepressants and Bipolar Depression
- Bipolar depression and major depressive disorder can look similar, but they require different treatment frameworks.
- Antidepressants are generally not used alone in bipolar I depression because they may contribute to mania or unstable cycling.
- Some patients may receive antidepressants as part of a carefully supervised combination plan, particularly in selected bipolar II presentations.
- Mood stabilizers and certain atypical antipsychotic medications have established roles in bipolar depression care.
- IV ketamine for bipolar depression is an off-label, adjunctive option supported by preliminary but limited evidence.
- SPRAVATO® and TMS should not automatically be presented as bipolar depression treatments simply because they are used for certain major depressive disorder presentations.
- Medication should never be stopped or changed without guidance from the prescribing clinician.
A More Careful Next Step for Mobile-Area Patients
When depression continues despite several medications, it is understandable to wonder whether anything will help. The next step should not be based on frustration alone. It should begin with a careful review of the diagnosis, prior treatment responses, mood-elevation history, current medications, and overall safety.
At Wholistic Health, we offer patients from Theodore, Mobile, and surrounding Gulf Coast communities an honest conversation about whether IV ketamine may have a place in their care. We do not promise that an interventional treatment will be recommended, and we do not treat one infusion service as a substitute for comprehensive bipolar management.
Our role is to listen to the full history, explain what the evidence does and does not show, and help determine whether our services are an appropriate addition to the existing plan.
To ask questions or discuss an evaluation, contact our Wholistic Health clinic in Theodore.
How We Approach Bipolar Depression at Wholistic Health
At Wholistic Health, we combine traditional medical care with a whole-person perspective that considers mental health, physical health, daily routines, and the individual’s treatment history.
Our clinic offers monitored IV ketamine for carefully selected patients with bipolar depression. Because this is an off-label use supported by a developing evidence base, we emphasize informed consent, realistic expectations, individualized screening, and coordination with existing care when appropriate.
We believe people deserve to understand why a treatment is being considered, how it fits into the larger plan, and where important uncertainties remain.
Works Cited
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., Machado-Vieira, R., Manji, H. K., & Zarate, C. A., Jr. (2010). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry, 67(8), 793–802. doi:10.1001/archgenpsychiatry.2010.90 https://pubmed.ncbi.nlm.nih.gov/20679587/
Fancy, F., Butt, M., Qureshi, N. A., Nagi, A., Lavoie, K. L., & Jawad, M. Y. (2023). Ketamine for bipolar depression: An updated systematic review. Therapeutic Advances in Psychopharmacology, 13, 20451253231202723. doi:10.1177/20451253231202723 https://pubmed.ncbi.nlm.nih.gov/37771417/
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. doi:10.1176/appi.focus.20230009 https://pubmed.ncbi.nlm.nih.gov/38695002/
National Institute of Mental Health. (2025). Bipolar disorder. U.S. Department of Health and Human Services. https://www.nimh.nih.gov/health/publications/bipolar-disorder
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., Tondo, L., Findling, R. L., Youngstrom, E. A., Tohen, M., Undurraga, J., González-Pinto, A., Goldberg, J. F., Yildiz, A., Altshuler, L. L., Calabrese, J. R., Mitchell, P. B., Thase, M. E., Koukopoulos, A., Colom, F., Frye, M. A., Malhi, G. S., Fountoulakis, K. N., Vieta, E., & Ghaemi, S. N. (2013). The International Society for Bipolar Disorders task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry, 170(11), 1249–1262. doi:10.1176/appi.ajp.2013.13020185 https://pmc.ncbi.nlm.nih.gov/articles/PMC4091043/
U.S. Food and Drug Administration. (2008). NeuroStar TMS Therapy System 510(k) summary. Center for Devices and Radiological Health. https://www.accessdata.fda.gov/cdrh_docs/pdf8/k083538.pdf
Janssen Pharmaceuticals, Inc. (2026). SPRAVATO® prescribing information. https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf
Medical Disclaimer
This content is provided for educational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any condition. Bipolar disorder requires individualized assessment and ongoing care from qualified mental health professionals.
IV ketamine for bipolar depression is an off-label use and is not FDA-approved for this indication. SPRAVATO® does not have an FDA-approved bipolar depression indication. NeuroStar TMS has specific FDA-cleared indications and should not be described as an FDA-cleared treatment for bipolar depression.
Do not start, stop, or change an antidepressant, mood stabilizer, antipsychotic medication, or other psychiatric treatment without guidance from the prescribing clinician. If you are experiencing a mental health crisis, symptoms of mania or psychosis, or thoughts of suicide, call or text 988, call 911, or go to the nearest emergency room.